Brief: Tempus Introduces xM, An Assay To Monitor Immunotherapy Response For Patients With Advanced Cancers
02/06/2025 13:35
June 2 (Reuters) - Tempus AI Inc TEM.O: TEMPUS INTRODUCES XM, AN ASSAY TO MONITOR IMMUNOTHERAPY RESPONSE FOR PATIENTS WITH ADVANCED CANCERS Source text: ID:nBw3rVlMZa Further company coverage: TEM.O ((Reuters.Briefs@thomsonreuters.com;))